Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study.
Timothy Francis Cloughesy
No relevant relationships to disclose
Paul S. Mischel
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
Consultant or Advisory Role - Novocure; Roche
Michael Prados
No relevant relationships to disclose
Patrick Y. Wen
No relevant relationships to disclose
Bin Wu
Employment or Leadership Position - Sanofi
Kevin Rockich
Employment or Leadership Position - Sanofi
Yi Xu
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Joanne J. Lager
Employment or Leadership Position - Sanofi
Stock Ownership - GlaxoSmithKline; Sanofi
Ingo K. Mellinghoff
No relevant relationships to disclose